Literature DB >> 17786228

The evolving biology and treatment of prostate cancer.

Russel S Taichman1, Robert D Loberg, Rohit Mehra, Kenneth J Pienta.   

Abstract

Since the effectiveness of androgen deprivation for treatment of advanced prostate cancer was first demonstrated, prevention strategies and medical therapies for prostate cancer have been based on understanding the biologic underpinnings of the disease. Prostate cancer treatment is one of the best examples of a systematic therapeutic approach to target not only the cancer cells themselves, but the microenvironment in which they are proliferating. As the population ages and prostate cancer prevalence increases, challenges remain in the diagnosis of clinically relevant prostate cancer as well as the management of the metastatic and androgen-independent metastatic disease states.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786228      PMCID: PMC1952634          DOI: 10.1172/JCI31791

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  118 in total

1.  Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Authors:  Christopher C Parker
Journal:  J Natl Cancer Inst       Date:  2004-10-06       Impact factor: 13.506

2.  The prostate cancer prevention trial: design, biases and interpretation of study results.

Authors:  Phyllis J Goodman; Ian M Thompson; Catherine M Tangen; John J Crowley; Leslie G Ford; Charles A Coltman
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

Review 3.  Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.

Authors:  Kevin A David; Matthew I Milowsky; Lale Kostakoglu; Shankar Vallabhajosula; Stanley J Goldsmith; David M Nanus; Neil H Bander
Journal:  Clin Genitourin Cancer       Date:  2006-03       Impact factor: 2.872

Review 4.  Hereditary prostate cancer: epidemiologic and clinical features.

Authors:  B S Carter; G S Bova; T H Beaty; G D Steinberg; B Childs; W B Isaacs; P C Walsh
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

Review 5.  RANK ligand inhibition with denosumab for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Expert Opin Biol Ther       Date:  2006-10       Impact factor: 4.388

6.  The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate.

Authors:  Yasutomo Nakai; William G Nelson; Angelo M De Marzo
Journal:  Cancer Res       Date:  2007-01-30       Impact factor: 12.701

7.  Detection and expression of human BK virus sequences in neoplastic prostate tissues.

Authors:  Dweepanita Das; Rajal B Shah; Michael J Imperiale
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

8.  Angiostatin induces and sustains dormancy of human primary tumors in mice.

Authors:  M S O'Reilly; L Holmgren; C Chen; J Folkman
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  57 in total

1.  Methanolic Fractions of Ornithogalum cuspidatum Induce Apoptosis in PC-3 Prostate Cancer Cell Line and WEHI-164 Fibrosarcoma Cancer Cell Line.

Authors:  Hamed Asadi; Mona Orangi; Dariush Shanehbandi; Zohreh Babaloo; Abbas Delazar; Leila Mohammadnejad; Fatemeh Zare Shahneh; Samira Valiyari; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2014-08-25

Review 2.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

3.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Authors:  Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

4.  Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.

Authors:  Byoung Heon Kang; Markus D Siegelin; Janet Plescia; Christopher M Raskett; David S Garlick; Takehiko Dohi; Jane B Lian; Gary S Stein; Lucia R Languino; Dario C Altieri
Journal:  Clin Cancer Res       Date:  2010-09-28       Impact factor: 12.531

Review 5.  Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis.

Authors:  Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

6.  [68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients.

Authors:  Jan-Carlo Janssen; Nadine Woythal; Sebastian Meißner; Vikas Prasad; Winfried Brenner; Gerd Diederichs; Bernd Hamm; Marcus R Makowski
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

7.  The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment.

Authors:  Kosuke Mizutani; Sudha Sud; Natalie A McGregor; Gari Martinovski; Brandon T Rice; Matthew J Craig; Zachary S Varsos; Hernan Roca; Kenneth J Pienta
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

8.  Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.

Authors:  Kosuke Mizutani; Sudha Sud; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2009-03-01       Impact factor: 4.429

Review 9.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

10.  The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells.

Authors:  Patricia Adamo; Sean Porazinski; Shavanthi Rajatileka; Samantha Jumbe; Rachel Hagen; Man-Kim Cheung; Ian Wilson; Michael R Ladomery
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.